公开(公告)号：US20240254078A1

公开(公告)日：2024-08-01

申请号：US18606722

申请日：2024-03-15

申请人： Hangzhou PhecdaMed Co., Ltd.

发明人： Hongguang XIA ,  Mengyang FAN ,  Xufeng CEN ,  Xiaoyan XU ,  Ronghai WU ,  Dong LIU ,  Zhen TIAN

IPC分类号： C07C311/21 ,  A61K31/18 ,  A61K31/337 ,  A61K31/381 ,  A61K31/402 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/433 ,  A61K31/44 ,  C07D207/06 ,  C07D231/18 ,  C07D249/04 ,  C07D249/12 ,  C07D257/04 ,  C07D261/10 ,  C07D285/06 ,  C07D305/08 ,  C07D333/34 ,  C07D333/62

CPC分类号： C07C311/21 ,  A61K31/18 ,  A61K31/337 ,  A61K31/381 ,  A61K31/402 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/433 ,  A61K31/44 ,  C07D207/06 ,  C07D231/18 ,  C07D249/04 ,  C07D249/12 ,  C07D257/04 ,  C07D261/10 ,  C07D285/06 ,  C07D305/08 ,  C07D333/34 ,  C07D333/62

摘要： The present application discloses small molecule compounds having a naphthylamine structure and an application thereof. In the present application, the structure of a compound having a structure as shown in general formula (I) is as shown in the drawing. The compound and the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof that are provided by the present application or the pharmaceutical composition provided by the present application can selectively induce autophagy in damaged mitochondria without affecting or only weakly affecting normal mitochondria, and further have superior metabolic stability and pharmacokinetic properties, lower toxicity, and better druggability.

公开(公告)号：US20240327340A1

公开(公告)日：2024-10-03

申请号：US18692114

申请日：2022-09-20

申请人： Hangzhou PhecdaMed Co., Ltd.

发明人： Hongguang XIA ,  Mengyang FAN ,  Xufeng CEN ,  Xiaoyan XU ,  Ronghai WU ,  Dong LIU ,  Zhen TIAN

IPC分类号： C07C317/34 ,  A61K31/18 ,  A61K31/40 ,  A61K31/41 ,  C07D207/04 ,  C07D249/04 ,  C07D257/04

CPC分类号： C07C317/34 ,  A61K31/18 ,  A61K31/40 ,  A61K31/41 ,  C07D207/04 ,  C07D249/04 ,  C07D257/04

摘要： The present application discloses small molecule compounds having a naphthylamine structure and an application thereof. In the present application, the structure of a compound having a structure as shown in general formula (I) is as shown in the drawing. The compound and the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof that are provided by the present application or the pharmaceutical composition provided by the present application can selectively induce autophagy in damaged mitochondria without affecting or only weakly affecting normal mitochondria, and further have superior metabolic stability and pharmacokinetic properties, lower toxicity, and better druggability.